Versartis International Trial in Adults With Long-Acting Growth Hormone

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Adult Growth Hormone Deficiency
Interventions
DRUG

somavaratan

Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly

Trial Locations (18)

3004

The Alfred Hospital, Melbourne

3065

St Vincent's Hospital, Fitzroy

4102

Princess Alexandra Hospital, Woolloongabba

10117

Charite-Universitätsmedizin, Berlin

75093

Endocrine Associates of Dallas, Plano

89128

Palm Research Center, Las Vegas

90048

Cedars-Sinai Medical Center, Los Angeles

92025

AMCR Institute Inc., Escondido

92653

Therapeutic Research Institute of Orange County, Laguna Hills

94305

Stanford University, Stanford

98122

Swedish Medical Center, Seattle

02114

Massachusetts General Hospital, Boston

02115

Brigham and Women's Hospital, Boston

D- 45147

Universitätsklinikum Essen, Essen

Unknown

Queen Elizabeth Hospital, Birmingham

William Harvey Research Institute, London

Hull Royal Infirmary, Hull, East Yorkshire

The Christie NHS Foundation Trust, Manchester

Sponsors
All Listed Sponsors
collaborator

Premier Research Group plc

UNKNOWN

lead

Versartis Inc.

INDUSTRY